{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T01:14:54Z","timestamp":1779930894220,"version":"3.53.1"},"reference-count":115,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,3,10]],"date-time":"2027-03-10T00:00:00Z","timestamp":1804636800000},"content-version":"am","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI174276"],"award-info":[{"award-number":["R01AI174276"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K22AI102769"],"award-info":[{"award-number":["K22AI102769"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI174875"],"award-info":[{"award-number":["R01AI174875"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1F32AI125096-01A1"],"award-info":[{"award-number":["1F32AI125096-01A1"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1F31AI131747-01A1"],"award-info":[{"award-number":["1F31AI131747-01A1"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32AI007245"],"award-info":[{"award-number":["T32AI007245"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["ARP-11746"],"award-info":[{"award-number":["ARP-11746"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HIV-1"],"award-info":[{"award-number":["HIV-1"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["pREJO.c\/2864"],"award-info":[{"award-number":["pREJO.c\/2864"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["ARP-8129"],"award-info":[{"award-number":["ARP-8129"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["ARP-2708"],"award-info":[{"award-number":["ARP-2708"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001680","name":"Charles H Hood Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001680","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1DP1DA060607"],"award-info":[{"award-number":["1DP1DA060607"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DP2DA040254"],"award-info":[{"award-number":["DP2DA040254"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017784","name":"Gilead Research Scholars Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017784","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunity"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.immuni.2026.01.031","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:40:15Z","timestamp":1772034015000},"page":"768-782.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV-vectored immunotherapy in humanized mice"],"prefix":"10.1016","volume":"59","author":[{"given":"Nicolas M.S.","family":"Galvez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D.","family":"Nitido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo Bin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cailin E.","family":"Deal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L.","family":"Boutros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yentli E.","family":"Soto Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan C.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maegan L.","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen Z.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Deymier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Bullock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serah","family":"Tanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarendra","family":"Pegu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Koup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Mascola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir D.","family":"Vrbanac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lingwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro B.","family":"Balazs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.immuni.2026.01.031_bib1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41579-023-00914-1","article-title":"Prevention, treatment and cure of HIV infection","volume":"21","author":"Landovitz","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.immuni.2026.01.031_bib2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-Yearly Lenacapavir or Daily F\/TAF for HIV Prevention in Cisgender Women","volume":"391","author":"Bekker","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.immuni.2026.01.031_bib3","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1016\/S2352-3018(20)30211-3","article-title":"Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models","volume":"7","author":"Jewell","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.immuni.2026.01.031_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/imr.12484","article-title":"Identification and specificity of broadly neutralizing antibodies against HIV","volume":"275","author":"McCoy","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.immuni.2026.01.031_bib5","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.cell.2018.03.061","article-title":"Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses","volume":"173","author":"Sajadi","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2026.01.031_bib6","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1128\/JVI.02853-13","article-title":"Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies","volume":"88","author":"deCamp","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.immuni.2026.01.031_bib7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","article-title":"Recent progress in broadly neutralizing antibodies to HIV","volume":"19","author":"Sok","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2026.01.031_bib8","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.cell.2015.03.004","article-title":"Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection","volume":"161","author":"Wu","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2026.01.031_bib9","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1126\/science.1213782","article-title":"Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design","volume":"334","author":"Diskin","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.immuni.2026.01.031_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/JVI.01791-15","article-title":"New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency","volume":"90","author":"Doria-Rose","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.immuni.2026.01.031_bib11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nm.3471","article-title":"Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission","volume":"20","author":"Balazs","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2026.01.031_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nature10660","article-title":"Antibody-based protection against HIV infection by vectored immunoprophylaxis","volume":"481","author":"Balazs","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2026.01.031_bib13","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/infdis\/jiw203","article-title":"Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo","volume":"214","author":"Deruaz","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.immuni.2026.01.031_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.virol.2014.05.036","article-title":"Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice","volume":"462\u2013463","author":"Stoddart","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.immuni.2026.01.031_bib15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.virol.2012.06.025","article-title":"Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model","volume":"432","author":"Veselinovic","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.immuni.2026.01.031_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn9662","article-title":"Antibody-mediated prevention of vaginal HIV transmission is dictated by IgG subclass in humanized mice","volume":"14","author":"Brady","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2026.01.031_bib17","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1128\/JVI.02213-14","article-title":"Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo","volume":"88","author":"Rudicell","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.immuni.2026.01.031_bib18","article-title":"Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail","volume":"9","author":"Julg","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2026.01.031_bib19","article-title":"Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge","volume":"9","author":"Julg","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2026.01.031_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01187-17","article-title":"Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys","volume":"91","author":"Julg","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.immuni.2026.01.031_bib21","doi-asserted-by":"crossref","first-page":"18921","DOI":"10.1073\/pnas.1214785109","article-title":"Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo","volume":"109","author":"Moldt","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2026.01.031_bib22","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.immuni.2026.01.031_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002435","article-title":"Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial","volume":"14","author":"Mayer","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.immuni.2026.01.031_bib24","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/s41591-022-01953-6","article-title":"Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition","volume":"28","author":"Gilbert","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2026.01.031_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01925-17","article-title":"Therapeutic Efficacy of Vectored PGT121 Gene Delivery in HIV-1-Infected Humanized Mice","volume":"92","author":"Badamchi-Zadeh","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.immuni.2026.01.031_bib26","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nature12744","article-title":"Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys","volume":"503","author":"Barouch","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2026.01.031_bib27","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","article-title":"Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys","volume":"563","author":"Borducchi","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2026.01.031_bib28","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.cell.2014.07.043","article-title":"Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice","volume":"158","author":"Halper-Stromberg","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2026.01.031_bib29","doi-asserted-by":"crossref","first-page":"16538","DOI":"10.1073\/pnas.1315295110","article-title":"HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice","volume":"110","author":"Horwitz","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.immuni.2026.01.031_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00498-17","article-title":"Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys","volume":"91","author":"Julg","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.immuni.2026.01.031_bib31","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature11604","article-title":"HIV therapy by a combination of broadly neutralizing antibodies in humanized mice","volume":"492","author":"Klein","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2026.01.031_bib32","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature12746","article-title":"Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia","volume":"503","author":"Shingai","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2026.01.031_bib33","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.immuni.2026.01.031_bib34","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2026.01.031_bib35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10\u20131074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2026.01.031_bib36","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1128\/JVI.03608-14","article-title":"HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies","volume":"89","author":"Lynch","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.immuni.2026.01.031_bib37","doi-asserted-by":"crossref","first-page":"11016","DOI":"10.1128\/JVI.01340-07","article-title":"Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection","volume":"81","author":"Mehandru","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.immuni.2026.01.031_bib38","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2026.01.031_bib39","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nm1244","article-title":"Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies","volume":"11","author":"Trkola","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2026.01.031_bib40","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.181496","article-title":"Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection","volume":"10","author":"Happe","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.immuni.2026.01.031_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals","volume":"24","author":"Bar-On","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2026.01.031_bib42","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1038\/s41591-024-03247-5","article-title":"Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1\/2a trial","volume":"30","author":"Julg","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2026.01.031_bib43","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/cei.12692","article-title":"Safety, Pharmacokinetics and Neutralization of the Broadly Neutralizing HIV-1 Human Monoclonal Antibody VRC01 in Healthy Adults","volume":"182","author":"Ledgerwood","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.immuni.2026.01.031_bib44","doi-asserted-by":"crossref","first-page":"8769","DOI":"10.1128\/JVI.76.17.8769-8775.2002","article-title":"Generation of Neutralizing Activity against Human Immunodeficiency Virus Type 1 in Serum by Antibody Gene Transfer","volume":"76","author":"Lewis","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.immuni.2026.01.031_bib45","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nbt1087","article-title":"Stable antibody expression at therapeutic levels using the 2A peptide","volume":"23","author":"Fang","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.immuni.2026.01.031_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005090","article-title":"AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity","volume":"11","author":"Fuchs","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2026.01.031_bib47","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature14264","article-title":"AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges","volume":"519","author":"Gardner","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2026.01.031_bib48","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/imr.12478","article-title":"Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention","volume":"275","author":"Brady","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.immuni.2026.01.031_bib49","doi-asserted-by":"crossref","first-page":"8334","DOI":"10.1128\/JVI.00908-15","article-title":"Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection","volume":"89","author":"Saunders","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.immuni.2026.01.031_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007395","article-title":"Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge","volume":"14","author":"Welles","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2026.01.031_bib51","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41591-022-01762-x","article-title":"Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial","volume":"28","author":"Casazza","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2026.01.031_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-63970-6","article-title":"Transient rapamycin treatment avoids unwanted host immune responses toward AAV-delivered anti-HIV antibodies","volume":"16","author":"Fuchs","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2026.01.031_bib53","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/s41586-025-09330-2","article-title":"Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life","volume":"645","author":"Ardeshir","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2026.01.031_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/v16060911","article-title":"The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention","volume":"16","author":"Thavarajah","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.immuni.2026.01.031_bib55","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.3646751","article-title":"Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms","volume":"236","author":"Koyanagi","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.immuni.2026.01.031_bib56","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1128\/JVI.06157-11","article-title":"Generation of Transmitted\/Founder HIV-1 Infectious Molecular Clones and Characterization of Their Replication Capacity in CD4 T Lymphocytes and Monocyte-Derived Macrophages","volume":"86","author":"Ochsenbauer","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.immuni.2026.01.031_bib57","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/13550289809113484","article-title":"HIV-1 Strain-Associated Variability in Infection of Primary Neuroglia","volume":"4","author":"McCarthy","year":"1998","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.immuni.2026.01.031_bib58","article-title":"The sources of adaptive variation","volume":"284","author":"Charlesworth","year":"2017","journal-title":"Proc. Biol. Sci."},{"key":"10.1016\/j.immuni.2026.01.031_bib59","doi-asserted-by":"crossref","first-page":"15951","DOI":"10.1073\/pnas.0604493103","article-title":"Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-\/-gamma c-\/- mice","volume":"103","author":"Baenziger","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2026.01.031_bib60","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1084\/jem.20062411","article-title":"Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1","volume":"204","author":"Sun","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.immuni.2026.01.031_bib61","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/nm1431","article-title":"Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1","volume":"12","author":"Melkus","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2026.01.031_bib62","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.immuni.2016.10.027","article-title":"Identification of a CD4-Binding Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth","volume":"45","author":"Huang","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.01.031_bib63","doi-asserted-by":"crossref","first-page":"17624","DOI":"10.1073\/pnas.1415789111","article-title":"Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex","volume":"111","author":"Sok","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2026.01.031_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms9443","article-title":"Dose\u2013response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies","volume":"6","author":"Webb","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2026.01.031_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/v16081320","article-title":"QuickFit: A High-Throughput RT-qPCR-Based Assay to Quantify Viral Growth and Fitness In Vitro","volume":"16","author":"Galvez","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.immuni.2026.01.031_bib66","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1586\/14787210.2.1.147","article-title":"The impact of the M184V substitution on drug resistance and viral fitness","volume":"2","author":"Wainberg","year":"2004","journal-title":"Expert Rev. Anti-infect. Ther."},{"key":"10.1016\/j.immuni.2026.01.031_bib67","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","article-title":"Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial","volume":"28","author":"Julg","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2026.01.031_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110199","article-title":"Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys","volume":"38","author":"Pegu","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2026.01.031_bib69","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2026.01.031_bib70","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1126\/science.aaf0972","article-title":"HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1","volume":"352","author":"Schoofs","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.immuni.2026.01.031_bib71","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2026.01.031_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007238","article-title":"Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies","volume":"14","author":"Otsuka","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2026.01.031_bib73","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1172\/JCI132779","article-title":"In vivo delivery of synthetic DNA\u2013encoded antibodies induces broad HIV-1\u2013neutralizing activity","volume":"130","author":"Wise","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.immuni.2026.01.031_bib74","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1016\/S2352-3018(25)00041-4","article-title":"Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults","volume":"12","author":"Wu","year":"2025","journal-title":"Lancet HIV"},{"key":"10.1016\/j.immuni.2026.01.031_bib75","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1128\/JVI.02658-10","article-title":"Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop","volume":"85","author":"Moore","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.immuni.2026.01.031_bib76","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00195-25","article-title":"Comprehensive maps of escape mutations from antibodies 10-1074 and 3BNC117 for Envs from two divergent HIV strains","volume":"99","author":"Radford","year":"2025","journal-title":"J. Virol."},{"key":"10.1016\/j.immuni.2026.01.031_bib77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1000660","article-title":"Recombination Rate and Selection Strength in HIV Intra-patient Evolution","volume":"6","author":"Neher","year":"2010","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.immuni.2026.01.031_bib78","doi-asserted-by":"crossref","first-page":"8954","DOI":"10.1128\/JVI.00754-11","article-title":"Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01","volume":"85","author":"Li","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.immuni.2026.01.031_bib79","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.chom.2019.08.014","article-title":"A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge","volume":"26","author":"Pegu","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.immuni.2026.01.031_bib80","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00443-19","article-title":"eCD4-Ig limits HIV-1 escape more effectively than CD4-Ig or a broadly neutralizing antibody","volume":"93","author":"Fellinger","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.immuni.2026.01.031_bib81","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.chom.2018.12.001","article-title":"HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design","volume":"25","author":"Bricault","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.immuni.2026.01.031_bib82","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.virol.2014.10.032","article-title":"Infection of monkeys by simian-human immunodeficiency viruses with transmitted\/founder clade C HIV-1 envelopes","volume":"475","author":"Asmal","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.immuni.2026.01.031_bib83","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1098\/rspb.1998.0552","article-title":"The effect of different immune responses on the evolution of virulent CXCR4\u2013tropic HIV","volume":"265","author":"Wodarz","year":"1998","journal-title":"Proc. Biol. Sci."},{"key":"10.1016\/j.immuni.2026.01.031_bib84","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-11-409","article-title":"Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape","volume":"11","author":"Theys","year":"2010","journal-title":"BMC Bioinform."},{"key":"10.1016\/j.immuni.2026.01.031_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.0020024","article-title":"Estimating Costs and Benefits of CTL Escape Mutations in SIV\/HIV Infection","volume":"2","author":"Ganusov","year":"2006","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.immuni.2026.01.031_bib86","doi-asserted-by":"crossref","first-page":"19727","DOI":"10.1073\/pnas.1206940109","article-title":"Stochastic effects are important in intrahost HIV evolution even when viral loads are high","volume":"109","author":"Read","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2026.01.031_bib87","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003878","article-title":"The Route of HIV Escape from Immune Response Targeting Multiple Sites Is Determined by the Cost-Benefit Tradeoff of Escape Mutations","volume":"10","author":"Batorsky","year":"2014","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.immuni.2026.01.031_bib88","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/QAD.0b013e32832ba8ec","article-title":"Antiretroviral medication adherence and the development of class-specific antiretroviral resistance","volume":"23","author":"Gardner","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.immuni.2026.01.031_bib89","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1128\/AAC.01505-10","article-title":"Replicative Fitness Costs of Nonnucleoside Reverse Transcriptase Inhibitor Drug Resistance Mutations on HIV Subtype C","volume":"55","author":"Armstrong","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.immuni.2026.01.031_bib90","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00109-012-0892-1","article-title":"Evolutionary dynamics of HIV at multiple spatial and temporal scales","volume":"90","author":"Hill","year":"2012","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.immuni.2026.01.031_bib91","doi-asserted-by":"crossref","DOI":"10.1093\/ve\/vex003","article-title":"In vivo mutation rates and the landscape of fitness costs of HIV-1","volume":"3","author":"Zanini","year":"2017","journal-title":"Virus Evol."},{"key":"10.1016\/j.immuni.2026.01.031_bib92","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2104651118","article-title":"Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody","volume":"118","author":"Meijers","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2026.01.031_bib93","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1128\/JVI.02712-06","article-title":"The Fitness Cost of Mutations Associated with Human Immunodeficiency Virus Type 1 Drug Resistance Is Modulated by Mutational Interactions","volume":"81","author":"Cong","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.immuni.2026.01.031_bib94","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/COH.0000000000000600","article-title":"Broadly neutralizing antibodies for the treatment and prevention of HIV infection","volume":"15","author":"Caskey","year":"2020","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.immuni.2026.01.031_bib95","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00126-20","article-title":"Key Positions of HIV-1 Env and Signatures of Vaccine Efficacy Show Gradual Reduction of Population Founder Effects at the Clade and Regional Levels","volume":"11","author":"Han","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.immuni.2026.01.031_bib96","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.34420","article-title":"Mapping mutational effects along the evolutionary landscape of HIV envelope","volume":"7","author":"Haddox","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.immuni.2026.01.031_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2001549","article-title":"Accurate predictions of population-level changes in sequence and structural properties of HIV-1 Env using a volatility-controlled diffusion model","volume":"15","author":"DeLeon","year":"2017","journal-title":"PLoS Biol."},{"key":"10.1016\/j.immuni.2026.01.031_bib98","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coviro.2015.05.002","article-title":"BLT humanized mice as a small animal model of HIV infection","volume":"13","author":"Karpel","year":"2015","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.immuni.2026.01.031_bib99","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1093\/infdis\/jit448","article-title":"Humoral immunity in humanized mice: a work in progress","volume":"208","author":"Seung","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.immuni.2026.01.031_bib100","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1016\/j.celrep.2016.07.074","article-title":"Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies","volume":"16","author":"McCoy","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2026.01.031_bib101","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2144","article-title":"Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller","volume":"9","author":"Freund","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2026.01.031_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12070879","article-title":"Humanized Mice for Studies of HIV-1 Persistence and Elimination","volume":"12","author":"Zhang","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.immuni.2026.01.031_bib103","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5501\/wjv.v5.i2.85","article-title":"Determination of 50% endpoint titer using a simple formula","volume":"5","author":"Ramakrishnan","year":"2016","journal-title":"World J. Virol."},{"key":"10.1016\/j.immuni.2026.01.031_bib104","doi-asserted-by":"crossref","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","article-title":"fastp: an ultra-fast all-in-one FASTQ preprocessor","volume":"34","author":"Chen","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1016\/j.immuni.2026.01.031_bib105","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.1923","article-title":"Fast gapped-read alignment with Bowtie 2","volume":"9","author":"Langmead","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.immuni.2026.01.031_bib106","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The Sequence Alignment\/Map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.immuni.2026.01.031_bib107","author":"Korber"},{"key":"10.1016\/j.immuni.2026.01.031_bib108","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1093\/bioinformatics\/bts480","article-title":"Snakemake\u2013a scalable bioinformatics workflow engine","volume":"28","author":"K\u00f6ster","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.immuni.2026.01.031_bib109","doi-asserted-by":"crossref","first-page":"11189","DOI":"10.1093\/nar\/gks918","article-title":"LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets","volume":"40","author":"Wilm","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.immuni.2026.01.031_bib110","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00804-18","article-title":"Metagenomic Sequencing of HIV-1 in the Blood and Female Genital Tract Reveals Little Quasispecies Diversity during Acute Infection","volume":"93","author":"Piantadosi","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.immuni.2026.01.031_bib111","doi-asserted-by":"crossref","first-page":"6884","DOI":"10.1128\/JVI.00667-16","article-title":"Measurements of Intrahost Viral Diversity Are Extremely Sensitive to Systematic Errors in Variant Calling","volume":"90","author":"McCrone","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.immuni.2026.01.031_bib112","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/1087057112465184","article-title":"Affordable Luciferase Reporter Assay for Cell-Based High-Throughput Screening","volume":"18","author":"Siebring-van Olst","year":"2013","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.immuni.2026.01.031_bib113","unstructured":"Borchers, H.W. (2023). Pracma: Practical Numerical Math Functions. Version R Package Version 2.4.4."},{"key":"10.1016\/j.immuni.2026.01.031_bib114","series-title":"R: A Language and Environment for Statistical Computing","year":"2024"},{"key":"10.1016\/j.immuni.2026.01.031_bib115","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J."}],"container-title":["Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107476132600052X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107476132600052X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:28:05Z","timestamp":1778797685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107476132600052X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":115,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S107476132600052X"],"URL":"https:\/\/doi.org\/10.1016\/j.immuni.2026.01.031","relation":{},"ISSN":["1074-7613"],"issn-type":[{"value":"1074-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV-vectored immunotherapy in humanized mice","name":"articletitle","label":"Article Title"},{"value":"Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.immuni.2026.01.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}